EV
Evonile Pharma Ltd (EVONILE)
₹1,379.80
Mkt cap
₹4,779 Cr
P/E ratio
74.40
P/B
5.25
Div yield
0.00%
ROE
11.60%
ROCE
16.30%
EPS (TTM)
₹18.55
Book value
₹263
52W range
562–2,178
Sector
Healthcare
Price history
Previous close
Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. [1] It imports various medicines to India from different sources across the globe. [2]
NSE EVONILEBSE 500672
Health check
Cautious
ValuationExpensive
ProfitabilityAverage
GrowthLow
TechnicalsNeutral
52-week range
−36.66% from high₹1,380
₹562+145.34% from low₹2,178
Current
₹1,379.80
Prev close
₹1,392.90
Day
−0.94%
Price performance
1D
−0.94%
1W
−9.25%
1M
−2.66%
3M
+10.63%
6M
+21.77%
1Y
+132.58%
YTD
+64.72%
Financials
Revenue, profit & margin
P/E ratio
74.4×
EVONILE is 129% above the sector median of 32.5×
EVONILE74.4×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 85 | 81 | 92 | 87 | 93 | 84 | 88 | 90 | 86 | 91 | 104 | 56 | |
| YoY Sales growth | -22% | +5% | +7% | +2% | +11% | +10% | +3% | -5% | +4% | -8% | +8% | +19% | -38% | |
| Expenses | 62 | 65 | 70 | 68 | 69 | 67 | 60 | 60 | 66 | 64 | 70 | 69 | 88 | |
| Operating Profit | 17 | 20 | 11 | 24 | 18 | 26 | 24 | 27 | 24 | 22 | 21 | 35 | -32 | |
| OPM % | 21% | 23% | 14% | 26% | 21% | 28% | 29% | 31% | 26% | 26% | 23% | 34% | -57% | |
| Other Income | 17 | 22 | 10 | 10 | 10 | 11 | 11 | 11 | 9 | 9 | 10 | 9 | -61 | |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 5 | |
| Depreciation | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 4 | |
| Profit before tax | 32 | 41 | 21 | 34 | 28 | 35 | 34 | 37 | 33 | 30 | 30 | 43 | -101 | |
| Tax % | 27% | 36% | 31% | 24% | 26% | 28% | 14% | 26% | 26% | 46% | 16% | 25% | -23% | |
| Net Profit | 24 | 27 | 15 | 26 | 20 | 25 | 29 | 28 | 24 | 16 | 25 | 32 | -78 | |
| EPS in Rs | 8.08 | 9.07 | 5.01 | 8.78 | 6.97 | 8.69 | 10.00 | 9.43 | 8.27 | 5.49 | 8.62 | 10.99 | -26.46 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| rights Rights 5:12 @ Premium Rs 855/- | — | 11 Nov '26 | 11 Nov '26 |
Shareholding
as of Sep 202670.68%Promoter
Promoters70.68%
FIIs1.21%1.05
DIIs1.50%0.15
Public26.61%1.20
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.70 | 4,51,538 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.07 | 1,78,180 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.69 | 1,24,195 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.48 | 1,19,990 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.56 | 1,16,360 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.88 | 1,14,518 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Evonile Pharma | ₹1,367.60 | 74.36 | 4,779 | 0.00% | −78 | −138.32% | 56 | −37.95% | 16.26% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,987 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts6
Credit ratings1
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Nov - Newspaper Publication w.r.t. the dispatch of Letter of Offer and issue materials for the Rights Issue of the Equity Shares of the Company.Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 13 NovShareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 13 NovAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript 6 Nov - Transcript of the Earnings Call held on Wednesday, November 04, 2026.Submission Of The Letter Of Offer In Connection With The Proposed Rights Issue Of The Partly Paid-Up Equity Shares Of The Company. 5 Nov - Evonile Pharma launches rights issue of 10,287,832 partly paid shares at ₹860, aggregating ₹8,847.54 million.






